Immunic Details Vidofludimus Calcium MS Strategy, Phase III Timeline at Leerink Conference [Yahoo! Finance]
Immunic, Inc. (IMUX)
Company Research
Source: Yahoo! Finance
vidofludimus calcium during a session at the Leerink Partners Global Healthcare Conference, emphasizing what they described as a differentiated mechanism that combines anti-inflammatory effects with potential neuroprotection. Dual mechanism highlighted: Nurr1 activation and DHODH inhibition CEO Daniel Vitt said what matters most to patients with MS is neuroprotection, because patients “are afraid of progression.” He described vidofludimus calcium as activating Nurr1, a nuclear receptor he said is “directly involved in neuroprotection,” while also inhibiting DHODH, an “established anti-inflammatory mechanism in multiple sclerosis.” ? Data Storage to Data Intelligence: Everpure's Big AI Era Rebrand Vitt said the molecule was originally developed as a more selective DHODH inhibitor intended to avoid kinase inhibition associated with Aubagio (teriflunomide) and related toxicities. He added that neuroprotective effects were observed clinically, prompting further investigation that
Show less
Read more
Impact Snapshot
Event Time:
IMUX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMUX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMUX alerts
High impacting Immunic, Inc. news events
Weekly update
A roundup of the hottest topics
IMUX
News
- Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus Calcium [Yahoo! Finance]Yahoo! Finance
- Immunic Conference: “Transformative” 2026 Ahead With Pivotal MS Data Due Late Year, NDA Next [Yahoo! Finance]Yahoo! Finance
- Immunic secures European patent for MS drug candidate vidofludimus calcium [Yahoo! Finance]Yahoo! Finance
- Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium [Yahoo! Finance]Yahoo! Finance
- Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus CalciumPR Newswire
IMUX
Earnings
- 11/13/25 - Beat
IMUX
Analyst Actions
- 2/9/26 - HC Wainwright
IMUX
Sec Filings
- 3/4/26 - Form SCHEDULE
- 3/4/26 - Form D
- 3/2/26 - Form DEF
- IMUX's page on the SEC website